Japan's MBL Licenses RIP-Chip to Envoy Therapeutics for Use in Drug Discovery Programs
March 15, 2011
Japan's MBL Licenses RIP-Chip to Envoy Therapeutics for Use in Drug Discovery Programs
Under the terms of the agreement, Jupiter, Fla.-based Envoy will use MBL's platform to discover biomarkers related to schizophrenia, Parkinson’s disease, Alzheimer’s disease, drug addiction, and epilepsy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Plans Suite of Focused Genotyping Chips, Sees Slight Delay in 'Resurgence' of GWAS Market
September 14, 2010 / BioArray News - Van Andel Research Institute To Run In-House Protein Arrays on Aushon BioSystems' 2470 Platform
May 14, 2010 / ProteoMonitor - Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 17, 2013 / BioArray News - European Consortium Investigating Molecular Basis of IBD
May 17, 2013 / GenomeWeb Daily News - GMU Team Builds Phosphoproteomic-based Pathway Activation Profiles of NCI-60 Cancer Cell Lines
May 17, 2013 / ProteoMonitor